Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dirk De Cuyper
Observed names:
D De Cuyper,
D. De Cuyper,
De Cuyper, Dirk,
Dirk de Cuyper,
de Cuyper, Dirk
Institution:
UCB Pharma (Belgium)
Observed institutions:
University of Bern,
University of California, San Francisco,
University Hospital of Bern,
Baylor University Medical Center,
Duke Medical Center,
Atlanta Gastroenterology Associates,
UCB Pharma (Belgium)
show all 7
OpenAlex ID:
A5081177071
Bimekizumab versus Secukinumab in Plaque Psoriasis
2021
·
Kristian Reich
, Richard B. Warren
, et al.
·
New England Journal of Medicine
·
465
Bimekizumab versus Adalimumab in Plaque Psoriasis
2021
·
Richard B. Warren
, Andrew Blauvelt
, et al.
·
New England Journal of Medicine
·
279
Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol
2015
·
Megan E.B. Clowse
, Douglas C. Wolf
, et al.
·
The Journal of Rheumatology
·
88
PDF
Use of endospore-forming bacteria as an active oxygen scavenger in plastic packaging materials
2011
·
Tom Anthierens
, Peter Ragaert
, et al.
·
Innovative Food Science & Emerging Technologies
·
65
PDF
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
2022
·
Georgios Kokolakis
, Richard B Warren
, et al.
·
British Journal of Dermatology
·
39
PDF
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
2023
·
Kenneth B Gordon
, Richard G Langley
, et al.
·
British Journal of Dermatology
·
37
PDF
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
2023
·
Diamant Thaçi
, Ron Vender
, et al.
·
British Journal of Dermatology
·
34
PDF
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
2024
·
Andrew Blauvelt
, April Armstrong
, et al.
·
Journal of the American Academy of Dermatology
·
16
Tu1320 Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From Safety Surveillance
2015
·
Uma Mahadevan
, Severine Vermeire
, et al.
·
Gastroenterology
·
11
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
2024
·
Mark Lebwohl
, Joseph F. Merola
, et al.
·
Journal of the American Academy of Dermatology
·
7
PDF
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
2021
·
RB Warren
, A Blauvelt
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
7
PDF
43878 Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
2023
·
Kilian Eyerich
, Alice B. Gottlieb
, et al.
·
Journal of the American Academy of Dermatology
·
4
OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance
2014
·
M.E.B. Clowse
, D.C. Wolf
, et al.
·
Annals of the Rheumatic Diseases
·
4
DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance
2014
·
U. Mahadevan
, S. Vermeire
, et al.
·
Journal of Crohn s and Colitis
·
4
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
2023
·
Andrew Blauvelt
, April Armstrong
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
3
PDF
OP0018 Pregnancy Outcomes with Trimesters of Maternal Exposure to Certolizumab Pegol: Prospective and Retrospective Reports from Safety Surveillance
2015
·
M.E. Clowse
, F. Förger
, et al.
·
Annals of the Rheumatic Diseases
·
3
Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
2021
·
K Reich
, A Blauvelt
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
P165 Bimekizumab impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) core domains for patients with psoriatic arthritis: results up to 2 years of treatment duration
2025
·
Joseph F Merola
, Philip J Mease
, et al.
·
Rheumatology
PDF
Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
2022
·
A Armstrong
, RG Langley
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
2022
·
Kenneth B Gordon
, Richard G Langley
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
2022
·
Andreas Pinter
, Bruce Strober
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
27468 Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
2021
·
Kristian Reich
, Yukari Okubo
, et al.
·
Journal of the American Academy of Dermatology
27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
2021
·
Bruce E. Strober
, Andreas Pinter
, et al.
·
Journal of the American Academy of Dermatology
Prospektive und retrospektive Sicherheitsberichte zum Ausgang von Schwangerschaften unter CERTOLIZUMAB PEGOL
2015
·
Clowse, M.
, Förger, F.
, et al.
·
German Medical Science (German Research Foundation)
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Results From Safety Surveillance
2014
·
Uma Mahadevan
, Séverine Vermeire
, et al.
·
The American Journal of Gastroenterology
Show more works
View as search
Works count:
28
Citation count:
1,067
H-index:
9
I10-index:
9
Year
Topic
Type